Objective

In recent years, therapeutic antibodies have proven to be effective and safe treatments for various diseases.  Understanding the binding of therapeutic antibodies to Fc receptors provides insights into their mechanism of action (MOA), efficacy, and safety. The interactions of therapeutic antibodies with fragment crystallizable gamma receptors (FcGRs) and neonatal Fc receptors (FcRn) can be measured in-vitro as indicators of antibody functional performance.  During early drug development, as potential therapeutic antibodies are selected and engineered, changes in Fc receptor affinity can be indicative of changes in effector function and serum half-life. When measured in scaled-up production, binding of therapeutic antibodies to Fc receptors can serve as a metric for quality control (QC).

AlphaLISA® biochemical Fc receptor binding assays provide easy, robust assays to measure binding of potential therapeutic antibodies to human Fc receptor proteins. We offer a portfolio of AlphaLISA Fc receptor binding kits for therapeutic antibody development and production. These chemiluminescent, no-wash assays facilitate the design and development of antibody therapeutics.